Abbott reports Q3 2026 results, reaffirms EPS guidance
Abbott reported strong Q3 2026 sales and adjusted EPS growth, reaffirming full-year guidance. They announced several key regulatory approvals. Company executives expressed optimism about sustainable growth.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed